QQ客服 官方微博 反馈留言

	Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial
	Xu, Wen; Mu, Yiming; Zhao, Jiajun; Zhu, Dalong; Ji, Qiuhe; Zhou, Zhiguang; Yao, Bin; Mao, Anhua; Engel, Samuel S.; Zhao, Bin
刊名	中国科学. 生命科学
	2017
卷号	60期号:3页码:225-238
关键词	type 2 diabetes oral antihyperglycemic agent metformin DPP-4 inhibitor glimepiride gliclazide repaglinide acarbose
DOI	10.1007/s11427-016-0409-7
URL标识	查看原文
公开日期	[db:dc_date_available]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4586479
专题	山东大学
作者单位	Department of Endocrinology and Metabolism, the Third Affiliated Hospital of Sun Yat-Sen University, Guangdong Provincial Key Laboratory of D
推荐引用方式 GB/T 7714	Xu, Wen,Mu, Yiming,Zhao, Jiajun,et al. Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial[J]. 中国科学. 生命科学,2017,60(3):225-238.
APA	Xu, Wen.,Mu, Yiming.,Zhao, Jiajun.,Zhu, Dalong.,Ji, Qiuhe.,...&Bi, 更多.(2017).Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial.中国科学. 生命科学,60(3),225-238.
MLA	Xu, Wen,et al."Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial".中国科学. 生命科学 60.3(2017):225-238.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。